stockcaps360 (34.88)

INSV AzaSite® The first ocular treatment of its kind

September 23, 2009 – Comments (0) | RELATED TICKERS: ISPH , PFE , CBRX

INSV is ready to soar ,The U.S. Census Bureau projects that the population over the age of 65 will increase from 35 million in 1999 to approximately 70 million by the year 2030.Company believes that this aging of the U.S. population, and similar trends in other developed countries, will contribute to increased demand for new and effective ophthalmic products. InSite Vision receives royalty payments from our two commercial products, AzaSite®. Sep. 14, 2009-- InSite Vision Incorporated (OTCBB: INSV) today announced that Inspire Pharmaceuticals, its commercial partner for AzaSite® (azithromycin ophthalmic solution) 1% in the U.S and Canada, has committed to increasing production of AzaSite in response to the manufacturing supply shortage of erythromycin ophthalmic ointment (0.5%). The U.S. Food & Drug Administration (FDA) has approved InSite Vision’s New Drug Application (NDA) for http://www.insitevision.com/ (azithromycin ophthalmic solution) 1% for the treatment of bacterial conjunctivitis.